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Introduction: The ability to deploy transcranial direct current stimulation (tDCS) at home is a key usability advantage to support scaling for pivotal clinical trials. We have established a home-based tDCS
protocol for use in clinical trials termed remotely supervised (RS)-tDCS.
Objective: To report the tolerability and feasibility of tDCS sessions completed to date using RS-tDCS in
clinical trials.
Methods: We analyzed tolerability (i.e., adverse events, AEs) reported in six Class I/II/III trials using RStDCS to study symptom outcomes over 10 to 60 daily applications. Across the six clinical trials, 308
participants (18e78 years old) completed an average of 23 sessions for a total of 6779 RS-tDCS administrations. The majority of participants were diagnosed with multiple sclerosis, and open-label trials
included those diagnosed with a range of other conditions (e.g., Parkinson's disease, post-stroke aphasia,
traumatic brain injury, cerebellar ataxia), with minimum-to-severe neurologic disability. Clinical trial
feasibility (i.e., treatment ﬁdelity and blinding integrity) was examined using two Class I randomized
controlled trials (RCTs).
Results: No serious AEs occurred. Across administrations, three sessions (0.04%) were aborted due to
discomfort, but no participant discontinued due to tolerability. The AEs most commonly reported by
participants were tingling (68%), itching (41%) and warmth sensation (42%) at the electrode site, and
these were equally reported in active and sham tDCS conditions. The two Class I RCTs resulted in rapid
enrollment, high ﬁdelity to treatment completion, and blinding integrity.
Conclusions: At-home RS-tDCS is tolerable, including when used over extended periods of time. Homebased RS-tDCS is feasible and can enable Class I tDCS clinical trial designs.
© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Transcranial direct current stimulation (tDCS) is a noninvasive
brain stimulation technique that passes a low intensity electric
current through electrodes placed on the scalp [1]. tDCS is targeted
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to modulate brain regions of interest for behavioral or clinical effect
[2]. Clinical trials of tDCS are now numbered in the hundreds,
spanning investigation of its use for the management of neurological and psychiatric conditions. Both human and mechanistic
trials show a cumulative beneﬁt across stimulation sessions [3e5],
presenting a practical obstacle for many investigators when participants are required to travel to the clinic or lab facility for daily
treatment. Deploying tDCS for home use in clinical trials, deﬁned by
the FDA as “users in any environment outside of a healthcare

https://doi.org/10.1016/j.brs.2022.04.014
1935-861X/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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We have completed six clinical trials at NYU Langone Health
using the RS-tDCS protocol. We report the aggregated tolerability
data across these trials, including for protocols administering tDCS
for extended treatment periods, and the feasibility of its use for the
completion of Class I RCTs.

facility” [6], can reach more participants and accommodate an
extended number of tDCS sessions that may be necessary for
adequate evaluation of its effect. There is a growing body of trials
using approaches to home-based delivery of tDCS ([7e16]), with
interest and urgency increasing in response to the COVID-19
pandemic [17].
Our lab has developed and veriﬁed a protocol to provide participants with home-based tDCS for use in our clinical trials
[18e21]. Utilizing live remote supervision at each administration
via videoconference, the protocol aims to replicate the standards of
onsite tDCS administration in the clinic or lab, and is referred to as
remotely supervised or RS-tDCS [20]. Similar supervised home-use
tDCS protocols are being implemented by investigators to study
tDCS in a range of conditions (e.g. Ref. [7e16]).
We initially developed and veriﬁed the RS-tDCS protocol in pilot
studies in individuals with MS (administering 244 RS-tDCS sessions) [18,19,22,23]. Due to the nature of the disease, participants
with MS range in age across the lifespan and have a diverse disease
course, characterized by variability and broad-spectrum symptoms
that can include cognitive and/or motor impairments as well as
symptoms including fatigue, pain and mood disturbances. Given
our goal to complete clinical trials of tDCS in the management of
multiple sclerosis (MS), our procedures have been optimized to
reach participants who are demographically diverse with varying
levels of neurological impairment and to allow for the simultaneous pairing with therapeutic cognitive or motor training.
Following its development, we have found that the RS-tDCS
protocol can be generalized for use in participants with other
neurological conditions. Our RS-tDCS protocol has been validated
for use in Parkinson's disease (PD) [24,25], and used in participants
with post-stroke aphasia, cerebellar ataxia, depression, neurocognitive disorders due to traumatic brain injury, and mild cognitive impairment [26e28]. RS-tDCS has been successfully
implemented at additional centers (e.g., for post-traumatic headache [29]), and we also provide at-home tDCS treatment through
our tDCS telehealth clinical program (n ¼ 113 patients have
received clinical treatment to date, with 4,660 at-home tDCS sessions delivered) [30].

2. Methods
We report here from our six Class I/II/III trials at NYU Langone
Health using the standardized RS-tDCS protocol [20] (Table 1). All
studies were approved by the NYU Langone Health IRB and participants signed an informed consent prior to their participation.
2.1. RS-tDCS eligibility criteria
RS-tDCS protocols required participants to be at least 18 years of
age, to have an estimated premorbid cognitive ability in at least the
average range, and to be without severe current cognitive impairment. These criteria were screened for with a measure of singleword reading recognition (WRAT-4). Accommodations for those
in the open-label trial for chronic neurological conditions with
impaired language and/or visual functions included the nonverbal
alternative tests of receptive vocabulary (Peabody Picture Vocabulary Test, 4th edition; PPVT-4) or expressive vocabulary (Wechsler
Abbreviated Scale of Intelligence, 2nd Edition; WASI-II). Current
level of cognitive impairment was estimated with the Symbol Digit
Modalities Test (SDMT; using cut off age-normative z-score
of < 3.0 SD).
Exclusion criteria for the RS-tDCS protocol included: (1) metal
implanted in the head or in the neck; (2) pregnant or breastfeeding;
(3) history of head trauma (e.g., head injury, brain surgery); (4)
history of or current seizure disorder; (5) presence of any skin
disorder or skin sensitive area near stimulation locations; (6) comorbid primary medical, neurological or psychiatric condition that
was judged to be contributing to the enrolling symptom targeted by
the clinical trial.
Full participant eligibility criteria varied by trial depending on
targeted outcome measures (see Table 1). Four of the six trials were

Table 1
Descriptive characteristics of the randomized double-blind controlled clinical trials and open-label trials using the RS-tDCS protocol.
Clinical Trial
Identiﬁer

Diagnosis, n
Participants

Time period

Study Design

Class I
NCT03838770

MS, 107

NCT03499314

MS, 64

Mar 2019eJun
2021
April 2018eOct
2021

Sham30
controlled RCT
Sham20
controlled RCT

Class II/III
NCT02746705

MS, 74

NCT03564496
NCT02746705
NCT03049969

April 2016
eSept 2018
MS, 32
Jul 2018eOct
2021
PD, 16
April 2016
eSept 2018
Major Depression, 3; Sept 2017e
Post-stroke Aphasia, Ongoing
3;
Neurocognitive
Disorder, 3;
MS, 2;
Chronic Fatigue
Syndrome, 1;
Idiopathic
Hypersomnia, 1;
Cerebellar Ataxia, 1;
Chronic Pain, 1

Number of
Sessions

tDCS Current
Intensity (mA)

Electrode
Montage

tDCS Duration Paired Activity
(min)

2.0

DLPFC

20

Cognitive Training

2.0

M1-SO

20

Manual Dexterity
Training

Sham20/40
controlled RCT
Open Label
20

2.0/2.5

DLPFC

20

Cognitive Training

2.0

DLPFC

20

Cognitive Training

Open Label

10

2.0

DLPFC

20

Cognitive Training

Open Label

Up to 60

2.0e2.5

DLPFC/cerebellar
montage

20

Cognitive Training,
Physical Exercise
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protocol guides the technician to instruct the participant in
corrective action (e.g., typically applying pressure to the electrode).
This high sensitivity to any change supports safety and helps to
maintain stimulation efﬁcacy. If there is any disruption in the
contact quality for more than 30 s, the device automatically and
gradually powers off, decreasing the current over 30 s. The device
also has an Abort function that gradually ramps down the current in
the event of undue pain or any desire to stop the stimulation to
support tolerability.
The device has a code-based unlocking function that uses
unique one-time activation codes for each stimulation session.
Codes are provided at the time of the RS-tDCS session to the
participant for device use by the supervising technician, as per the
protocol.
Blinding and Sham Procedures: In the double-blind, shamcontrolled RCTs, tDCS procedures were the same for active and
sham tDCS. To maintain double blinding integrity, devices were
pre-programmed in advance by an independent staff member who
did not interact with the participant for the daily session or
outcome assessments. For active tDCS, the device was programmed
to ramp up to the target current intensity (for 30-s), provide constant current throughout the session (19 min), and then ramp down
at the end (for 30-s). For sham tDCS, the device was programmed
according to convention to ramp up to target current intensity (for
30-s) followed by a ramp down (30-s), with no current delivery for
18 min, and then ramp up (for 30-s) and down (for 30-s) at the end.

studies of participants with MS; an open-label trial included participants with PD, and the remaining trial enrolled participants
with a range of other conditions. All participants were required to
have a medically conﬁrmed diagnosis of their presenting condition
per trial deﬁnition, with stable disease and no change in any
medication for at least one month prior to enrollment.

2.2. RS-tDCS equipment
The participants were loaned a study kit for the duration of their
trial participation that included three key components to enable
the RS-tDCS protocol (Fig. 1):
tDCS Device: All trials used a 1  1 mini-CT tDCS device (Soterix
Medical Inc.). The mini-CT tDCS device is equipped with multiple
safety features to allow at-home use. The device contains contact
quality monitoring and control systems that update performance
and feedback >1000 times per second. During the stimulation
period, the 1  1 mini-CT device shows in real time the contact
quality of the electrode using simple category levels: Poor vs.
Moderate/Good. The stimulation will not start until adequate contact quality is achieved (Moderate/Good). Once adequate contact
quality is achieved, it is rare for the contact quality to drop. If the
contact quality moves to “Poor” during the stimulation period, the
participant and the study technician are alerted by the device
beeping continuously. The device will pause automatically if the
contact quality is not restored, accompanied by an alert sound. The

Fig. 1. RS-tDCS Equipment. (1) 1  1 mini-CT tDCS device: pre-programmable session type (active, sham), stimulation duration, and current intensity; generation of single-use
“unlock-code” for pre-programmed dose. (2) SNAPstrap headgear: “cap”-like placement for simple positioning and uniform electrode placement; (2a) markers for guidance in
placement; (2b) electrode polarity labeling with ﬁxed wiring. (3) SNAPpad: (3a) individually-packaged pre-moistened sponge; perforated packaging for easy opening; (3b) snap
connectors.
709
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Study Laptop: Pre-conﬁgured laptops were provided to the
participant with a HIPAA-compliant video conferencing software
(VSee), a remote monitoring software (TeamViewer), and the study
session data reporting software. Depending on trial design and
treatment outcomes, participants were also provided with additional software and/or equipment to complete the paired training
activity (see Table 1).

An exception was the sham programming for Trial NCT03838770
that included three periods of 60-s ramp up/down (beginning,
midway, and end).
Headset and Electrodes: RS-tDCS used the Soterix Medical
SNAPstrap headset that allows robust ﬁxed position electrode
placement for precise reproduction of a variety of montages. The
headset included pre-saturated sponge electrodes (SNAPpads) in
single use individual packaging for easy “snap” placement onto the
headset for each session (Fig. 1). This speciﬁc headset ensures
reliability of current ﬂow and has been demonstrated to be
consistent when tDCS is administered either onsite or from home
[31,32]. As reported in Fig. 2, the electrode montages included in
our trials were:

2.3. RS-tDCS protocol
An initial visit (in person or remote) was provided for device
orientation, training, and tDCS tolerability testing. All remaining
tDCS sessions were then completed by the participant from home
and monitored by study technicians in real time via videoconference. The supervising tDCS technicians were research lab personnel
who completed our standardized training to administer the RStDCS protocol for daily sessions, ranging in background from
doctoral level neurology faculty (PhD/MD) to advanced student
interns.
Initial Baseline Training Visit: After the study screening visit,
participants progressed through a series of checkpoints and
training procedures following the standardized RS-tDCS protocol
[18e20] (Fig. 2).

A. DLPFC montage, with the anode placed over the left dorsolateral
prefrontal cortex (DLPFC) and the cathode over the right DLPFC
(F3-F4, according to 10e20 EEG system);
B. M1-SO montage, with the anode placed over the left primary
motor cortex and the cathode over the contralateral supraorbital
area (C3-Fp2, according to 10e20 EEG system);
C. Cerebellar montage, with the anode placed over the cerebellum
region (O2, according to 10e20 EEG system) and the cathode on
the right shoulder.

Fig. 2. Operationalization of daily RS-tDCS session. At-home setup, live supervision, electrode montages (A: DLPFC; B: M1-SO, C: Cerebellar), and RS-tDCS protocol.
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duration. AE occurrences were examined by the percent of participants reporting an AE in at least one of their tDCS sessions, as well
as by the percent of sessions in which an AE was reported. Then, we
reported the percent of participants endorsing an AE in relation to
stimulation condition (active, sham tDCS), current intensity (2.0,
2.5 mA), electrode montage (DLPFC, M1-SO) and population characteristics (e.g., clinical characteristics, sex, age). Chi-Square
Fisher's Exact Test was used to assess whether the percent of participants endorsing each AE differed across the independent variables. We utilized Cochran's Q test to assess differences in the
percent of participants reporting AEs of tingling, itching and
warmth sensation at different time points (20 M1-SO sessions, 30
DLPFC sessions). Analyses were performed using SPSS 25.0. Level of
statistical signiﬁcance was set at 0.05 for all analyses.

Baseline Tolerability Test: During the initial visit, participants
completed a 90-s tolerability and dose selection test. The 90-s
tolerability test was performed with a standardized procedure by
using the Tolerability function of the Soterix Medical mini-CT device. Testing begins at the electrical current intensity as deﬁned by
the study protocol (e.g., 2 mA or 2.5 mA). During the tolerability
test, the current intensity is ramped up to the target intensity and
then down over a 90-s period, with tolerability determined by
participant ratings below 7 on the 0e10 Visual Analogue Scale
(VAS) of pain. Participants unable to tolerate the target current
intensity were given the option to proceed with another tolerability
test at a lower amperage (reduced by 0.5 mA). In the event that this
lower amperage was also intolerable, the participant was excluded
from further participation in the study. The current intensity
determined during the tolerability test was delivered during the
duration of the intervention.
Daily RS-tDCS Sessions: Sessions were conducted daily Monday
through Friday for 20 min with the electrical current intensity set
between 1.5 and 2.5 mA as deﬁned by the study protocol and individual participant tolerability levels determined at the baseline
visit. The technician guided the headset placement and visually
conﬁrmed the correct position using the headset markers for
guidance. When ready to begin, the participant was then provided
with their single-use code to activate the daily session.

3. Results
3.1. RS-tDCS participants and sessions
Overall n ¼ 308 participants enrolled in 6 trials for a total of
6,779 sessions (see Table 2), with an average of 23 ± 9.5 sessions
(ranging from 10 to 60) completed per participant. Total sessions
were 3,137 blinded active, 2,708 sham, and 934 open label active.
See Table 2 for a breakdown of assigned conditions, sessions, and
montages by trial. The full sample was 70% female with a mean age
of 50.26 ± 13.01 [18e78] years; 230 participants (75%) were White,
54 (18%) were African American/Black, 6 (2%) were Asian, and the
remaining 15 (5%) were unknown or not reported; 14 (9%) were
Hispanic/Latino. Participants were enrolled in clinical trials targeting fatigue, cognitive and/or motor dysfunction due to MS
(n ¼ 277) or PD (n ¼ 16), or enrolled in an open-label study targeting symptoms of major depression (n ¼ 3), post-stroke aphasia
(n ¼ 3), MS (n ¼ 2), cerebellar ataxia (n ¼ 1), idiopathic hypersomnia (n ¼ 1), chronic pain (n ¼ 1), chronic fatigue syndrome
(n ¼ 1), or neurocognitive disorders (n ¼ 3) due to traumatic brain
injury (TBI) or mild cognitive impairment (MCI).
For the initial baseline training session, 244 sessions were
completed onsite, and 64 were completed remotely (as an accommodation to continue enrollment during COVID-19). Therefore,
of the 6,779 total sessions administered, 6,535 RS-tDCS sessions
were delivered to the participant at home or another location
outside the clinic.

2.4. Session discontinuation criteria
During the session, the study technician captured any pain or
discomfort spontaneously reported and with a speciﬁc query at the
midpoint of the session. If the participant reported pain or
discomfort at any point, they were asked to rate the intensity (VAS
0e10). In the event of pain related to stimulation that was rated
higher than 7 on the VAS, the session was paused for review with
the study technician. The protocol provides the option to abort the
session, or resume the session based on participant feedback and
repeated VAS administration. If the reported discomfort resolved
and was addressed, the participant could choose to continue the
session (see Fig. 1).
2.5. AE reporting
At the end of each stimulation session, participants were asked
about any side effects that they experienced. In the absence of
established AE reporting for the tDCS ﬁeld, this process was initially
completed with a rating of 11 potential AEs (adapted from Brunoni
et al., 2011 [33]) for occurrence, intensity and duration. In addition,
participants could also report other treatment-related experiences
for AE reporting capture. Based on the predominant reporting of
tingling/itching/warmth sensations across ratings and inconsistent
endorsement of any other AE, we moved this process to a branched
logic screen capture (vs. technician recording) delivered through an
in-house software program developed speciﬁcally for use in RStDCS trials. Here, when a participant reported an AE, they were
ﬁrst asked about these three AEs, followed by a spontaneous capture of any “Other” AE experienced rather than continued
prompting of each checklist item. In both the written checklist and
the automated screen capture, participants were asked to report AE
intensity on the VAS and the duration in minutes as guided by the
tDCS technician.

3.2. Tolerability: clearance and session discontinuations
No serious AEs [34] occurred in any of the trials.
Enrollment tolerability testing resulted in n ¼ 1 trial participant
of the 308 enrolled (<0.5%) excluded (>7/10 VAS pain rating),
resulting in study withdrawal. A total of n ¼ 2 participants were
unable to tolerate the target current intensity of 2.0 mA and, per
protocol, were lowered to 1.5 mA for the treatment period.
No participant was discontinued due to tolerability after starting
the trial. Single session limiting AEs, (deﬁned as VAS rating for pain/
discomfort >7) occurred in 27 (0.4%) of all administered sessions
(n ¼ 22 participants: 4 blinded active, 10 blinded sham, 8 open
label), which resulted in 3 sessions being aborted (n ¼ 3 participants: n ¼ 2 received active tDCS and n ¼ 1 sham tDCS).
No participants were discontinued from the trials because of
training or technical difﬁculties, regardless of whether the initial
baseline training was conducted in-person or remotely.
Reported AEs: AE reporting was tabulated by total number of
participants, occurrence across total number of sessions, and
within participants across sessions (see Table 3). All AEs were reported to be mild to moderate in intensity and did not lead to study
discontinuation for any participant. There was no overall difference

2.6. Statistical analyses
We used descriptive statistics to summarize the clinical and
demographic characteristics, trial enrollment, and completion
rates. An AE occurrence was coded if reported at any intensity or
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Table 2
Summary of total sessions and participants by electrode montage and tDCS condition.

Electrode Montage
DLPFC
M1-SO
Cerebellar

Blinded Active
#sessions (n participants)

Sham
#sessions (n participants)

Open Label
#sessions (n participants)

2500 (97)
637 (35)
e

2160 (84)
548 (29)
e

874 (62)
e
60 (1)

sensation (c2 (29) ¼ 30.99, p ¼ 0.366; c2 (29) ¼ 23.56, p ¼ 0.750)
across 30 DLPFC daily tDCS sessions.

in reporting of frequency of tingling, itching and warmth sensation
between the checklist reporting and the automated software program (tingling: 75% vs. 60%, c2 ¼ 2.78, p ¼ 0.058; itching: 45.6% vs.
35.4%, c2 ¼ 1.39, p ¼ 0.388; warmth sensation: 32.50% vs. 23.9%,
c2 ¼ 2.78, p ¼ 0.064, respectively).
Most Common AEs Reported: The most consistently reported
AEs across sessions included tingling (30.7%, 2,084/6,779), warmth
sensation (16.3%, 1,106/6,779) and itching (11.9%, 808/6,779). AEs
indicated at least once by participants were tingling, warmth
sensation and itching: 68% (210/308), 42% (128/308), and 41% (125/
308), respectively. Participants with MS did not differ in reporting
compared to those with a range of other conditions (within openlabel active participants): (72.2% vs. 83.9%, c2 ¼ 1.99, p ¼ 0.159),
itching (36.11% vs. 43.1%, c2 ¼ 1.23, p ¼ 0.266), and warmth
sensation (31.3% vs. 41.9%, c2 ¼ 0.78, p ¼ 0.378).
Overall, the intensity of these reports was mild (median value on
the VAS 0e10: 2.0) and transient in nature (average duration:
4.3 ± 2.1 min). In the blinded trials, there was no difference between blinded active vs. sham in the percent of participants
reporting tingling (49.6% vs. 62.3%, c 2 ¼ 3.98, p ¼ 0.054), itching
(41.6% vs. 53.3%, c2 ¼ 3.96, p ¼ 0.054) and warmth sensation (29.8%
vs. 30.7%, c 2 ¼ 0.25, p ¼ 0.874). In the DLPFC 2.0 mA trials, there
was a slightly higher rate of reporting of the tingling sensation
among participants receiving active stimulation as open-label
(n ¼ 63) vs. blinded (n ¼ 97) (76.2% vs. 50.5%, c2 ¼ 10.55,
p ¼ 0.001).

3.4. Other reported AEs
As with the three most commonly reported AEs noted above, no
other AEs led to discontinuation (Fig. 4). The frequency of occurrence of other AEs was low (i.e., less than 10%) across the RS-tDCS
participants.
3.5. Electrode montage and stimulation intensity
We next tested whether the tDCS montage or current intensity
inﬂuenced AE reporting rate. To identify any relation between AE
occurrence and electrode montage, we analyzed the overall blinded
active sessions (DLPFC vs. M1-SO; n ¼ 97 and n ¼ 35 participants,
respectively). We did not ﬁnd any difference in the percent of
participants reporting tingling (c2 ¼ 0.10, p ¼ 0.764), itching
(c2 ¼ 0.09, p ¼ 0.828), and warmth sensation (c2 ¼ 2.192, p ¼ 0.139)
between DLPFC and M1-SO electrode montages.
To examine AEs by current intensity, we compared the two
active blinded DLPFC tDCS conditions of 2.0 mA (n ¼ 38 participants) vs. 2.5 mA (n ¼ 21 participants). Those receiving 2.5 mA
reported slightly higher rates of warmth sensation compared to
those receiving 2.0 mA (33.3% vs. 25.7%; c2 ¼ 4.87, p ¼ 0.048), but
no difference in tingling (c2 ¼ 0.471, p ¼ 0.493) and itching
(c2 ¼ 0.466, p ¼ 0.623).

3.3. Consistency in AE reporting across repeated sessions

3.6. Feasibility in class I RCTs

Using our two completed double-blinded RCTs, we pooled all
participants who received either active or sham tDCS and
completed either 20 consecutive sessions of M1-SO tDCS or 30
consecutive sessions of DLPFC tDCS. Itching, tingling, and warmth
sensation persisted over time and were consistently reported at
each session across both active and sham participants (Fig. 3). There
were no signiﬁcant differences in the proportion of participants
who reported tingling (active/sham tDCS: c2 (19) ¼ 16.57,
p ¼ 0.619; c2 (19) ¼ 23.21, p ¼ 0.228), itching (c2 (19) ¼ 25.72,
p ¼ 0.138; c2 (19) ¼ 13.21, p ¼ 0.828), and warmth sensation (c2
(19) ¼ 21.10, p ¼ 0.332; c2 (19) ¼ 14.81, p ¼ 0.735) across the 20 M1SO daily tDCS sessions. Similarly, there was no difference in the
proportion of participants reporting tingling (active/sham tDCS: c2
(29) ¼ 18.24, p ¼ 0.939; c2 (29) ¼ 23.05, p ¼ 0.774), itching (c2
(29) ¼ 38.78, p ¼ 0.109; c2 (29) ¼ 24.19, p ¼ 0.719), and warmth

We employed the RS-tDCS protocol to complete two doubleblind, sham-controlled RCTs (Table 1), targeting the MS symptoms of fatigue (30 sessions of tDCS paired with cognitive training)
and upper extremity impairment (20 sessions of tDCS paired with
manual dexterity training). Table 1 shows the demographic and
clinical features for each trial. Enrollment of both trials was robust,
including during the period of the COVID-19 pandemic, due to the
remote access for participation. During April 2019eFebruary 2021
(22 months), we enrolled n ¼ 120 participants for the study targeting fatigue. The study targeting upper extremity motor functioning recruited participants with more advanced disability level,
with n ¼ 66 participants enrolled during April 2018eOctober 2020
(30 months).
There was a high rate of ﬁdelity to treatment and protocol
completion for both studies. In the RCT #1 (NCT03838770),

Table 3
Percentage of participants who endorsed tingling, itching, and warmth sensation in at least one RS-tDCS session broken down by condition (active vs. sham) and electrode
montage (DLPFC vs. M1-SO). The table includes only participants with MS.
DLPFC

Tingling, %
Itching, %
Warmth Sensation, %

M1-SO

Active n ¼ 97 participants

Sham n ¼ 84 participants

Active n ¼ 35 participants

Sham n ¼ 29 participants

50.5
39.1
26.8

63.1
44.6
34.5

48.6
45.7
38.2

66.6
34.4
20.0
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Fig. 3. AE reporting across daily repeated applications. Daily occurrence rate (%) of AEs reported across 30 DLPFC RS-tDCS sessions from n ¼ 54 active and n ¼ 52 sham participants and 20 M1-SO RS-tDCS sessions from n ¼ 34 active and n ¼ 30 sham participants.

Fig. 4. Other AEs reported. Percentage of participants reporting an AE in one or more sessions by tDCS condition, gender, and age (50 years vs. 51 years). The active tDCS
condition includes blinded and open-label administration. No difference in AE reporting was found among factors (all p's > 0.05).
713

G. Pilloni, A. Vogel-Eyny, M. Lustberg et al.

Brain Stimulation 15 (2022) 707e716

targeting fatigue and cognition, 92.0% of participants completed 25
or more sessions, with 67.2% participants completing all 30 sessions. In the RCT #2 (NCT03499314), targeting upper extremity
motor function, 95% of participants completed all 20 RS-tDCS sessions, with 98% completing at least 18/20.
Both trials met criteria for adequate participant blinding, identifying condition assignment with 53% accuracy for RCT #1 and 36%
for RCT #2, both falling within a generally acceptable target of
35e65% [35e37]. The trials differed in montage (M1-SO vs. DLPFC),
number of sessions (20 vs. 30), and sham procedure (conventional
ramp up/down vs novel three ramp up/down periods). RCT #1
administered 20 M1-SO sessions using the conventional sham of
initial ramp up/down period at the beginning, and RCT #2
employed a novel three period ramp up/down procedure. Further,
the percent of active and sham participants who accurately guessed
whether they received active or sham stimulation did not differ in
both RCTs (c2 ¼ 2.24, p ¼ 0.134; c2 ¼ 3.22, p ¼ 0.073, respectively).

“brieﬂy supervised” model with live connection for initial “clearance” at the beginning of the daily session versus monitoring
throughout the entire session to its completion. While it is clear
that live real-time connection with participants at their sessions
results in higher treatment ﬁdelity [7], this model of hybrid full and
more limited session monitoring has been successfully demonstrated (e.g., Alonzo et al., 2019 [8], Loo et al., 2017 [45]) and
enabled by current technology advances.

4. Discussion

LC is supported by grants from NIH:1R01NS112996-01A,
R21NS101712-0, US Department of Defense: W81XWH-17-1-0320,
VA Healthcare: GRANT13010404, National MS Society: RG-180330492, RFA-2104-37483, and NIDA-NIH: R21DA055427. MB is
supported by grants from Harold Shames and the National Institutes of Health: NIH-NIDA UG3DA048502, NIH-NIGMS
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NIH-NINDS
1R01NS112996,
NIH-NINDS
1R01NS101362, NIH-NIMH 1R01MH111896, and NIH-NINDS
1R01NS095123. AD is supported by grants from: NIH-NIDA
75N95020C00024,
DoD-DARPA:
W912CG21C0014,
ED:
91990021C0032. GP is supported by grants from National MS Society: RFA-2104-37483, and NIDA-NIH: R21DA055427.

5. Conclusions
Home-based tDCS is tolerable using the RS-tDCS protocol. The
RS-tDCS protocol provides an option to reach larger sample sizes
and deliver tDCS over extended treatment periods in RCTs.
Funding source

Our ﬁndings demonstrated the tolerability and feasibility of
tDCS delivered to participants at home and over extended time
periods in the largest sample reported to date (e.g., up to 60 sessions) [38]. Using the RS-tDCS protocol, tDCS was found to be
tolerable and feasible in a diverse range of participants and for
repeated applications over time. Our ﬁndings extend the established record of safety and tolerability of tDCS [34,39] to include
supervised use in the home setting.
Across the 6,779 sessions reported here, the most common AEs
were related to the electrode site for both active and sham tDCS:
tingling, itching and sensations of warmth. Together, these AEs
were commonly reported at each session, were not treatment
limiting, and resolved by session completion. In addition, there was
no signiﬁcant change in incidence across repeated exposure,
demonstrating the tolerability of tDCS across sessions well beyond
the conventional number of sessions (e.g., less than 10 sessions
[40]) in the majority of the clinical trials to date. Furthermore, this
more extensive exposure did not increase the risk of AEs with
repeated application over time (including risk for skin lesion) [41].
Provided rigorous protocols and proper equipment is used [41],
our ﬁndings are broadly consistent with the tolerability reported
for tDCS across the large body of clinical trials to date
[1,38,39,42,43], with common AEs being mild (tingling, warmth,
itching) and transient. Speciﬁc rates of AEs will depend on the exact
protocol and equipment utilized. For example, our RS-tDCS reported incidences of head discomfort or pain, including over the
cumulative application in our extended protocols, were lower
compared to prior reports [33,38,44]. This discrepancy in AE rates
may be attributed to our use of speciﬁc headsets rather than elastic
rubber bands.
Limitations of our analyses include that the majority of our RStDCS use to date is in participants living with MS. However, while
all have one common diagnosis, the diversity of MS symptom
presentation and patient populations provide a robust sample to
inform the more generalized use of tDCS for symptomatic or
rehabilitative applications. Participants with MS varied across the
adult age span, with minimal to more severe levels of cognitive or
motor involvement, and a broad range of potential symptoms
experienced (e.g., fatigue, pain, and other motor, sensory and mood
disturbances).
We used our speciﬁc protocol of RS-tDCS for all sessions,
including live supervision and a structured paired activity during
the stimulation period. While live supervision for all sessions may
not be possible for many centers, we believe that our demonstration of its tolerability can allow for participants to be moved to a
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